Distribution of prostaglandins in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients: effects of aspirin and paracetamol

S J KONTUREK,* W OBTULOWICZ, E SITO, J OLEKSY, S WILKON, AND A KIEC-DEMBINSKA

From the Institute of Physiology and Pharmacology, Medical Academy and District Hospital, Krakow, Poland

SUMMARY The distribution of mucosal PGE₂-like activity was determined by bioassay technique in the body and antrum of the stomach and in the duodenum of healthy subjects and duodenal ulcer patients before and after administration of aspirin, paracetamol, or histamine. In healthy subjects, the oxyntic, antral and duodenal mucosa was found to be capable of generating large amounts of PGE₂, which were not significantly different from those found in duodenal ulcer patients. No correlation was found between the generation of PGE₂ and gastric acid secretory status or serum gastrin level. Aspirin—and to a much lesser extent, paracetamol—caused a dramatic reduction in the ability of the gastric mucosa to biosynthesise PGE₂ and this was accompanied by marked side-effects and injury to the gastric mucosa. Administration of histamine caused small but significant reduction in the biosynthesis of PGE₂ but it was accompanied by marked mucosal damage. This study indicates that the gastric and duodenal mucosa is capable of generating PGE₂-like activity which may be involved in the mechanism that protects the mucosa against the damage caused by aspirin.

Human gastric mucosa has been shown to release prostaglandins under basal conditions and in response to secretory stimulation.¹⁻³ It has been postulated that prostaglandins may play a role in the control of gastric secretion⁴ and in the protection of gastric mucosa against physical or chemical injury.⁵ It has been suggested that the deficiency of mucosal prostaglandins is an important aetiological factor in peptic ulcer disease^{6,7} but no information is available regarding the generation and distribution of prostaglandins in human gastric mucosa.

This study was undertaken to determine the distribution of prostaglandins in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients and to examine the effects of non-steroidal anti-inflammatory compounds and histamine administration on the generation of mucosal prostaglandins.

Methods

SUBJECTS

The study population was made up of 27 healthy volunteers with no previous history of gastrointestinal disease, bleeding disorders, or drug intolerance and 25 patients with active duodenal ulcer confirmed by endoscopy. Their average age was 28 years (range 20-34 years). They were not taking H₂-blockers or anticholinergic drugs and had discontinued antacids for at least 24 hours before the examination. The study was approved by the Human Research Review Committee and informed consent was obtained from all participants after the nature of study has been fully explained.

The examination started in early morning after a 12 hour fast, and a venous blood sample was taken from all subjects for serum gastrin and salicylate determination. Then intravenous diazepam was given as premedication and gastro-duodenal endoscopy was performed with the Olympus GIF-D₂ (Japan) endoscope. Four or five biopsy samples were obtained from the stomach body and antrum and the

*Address for correspondence: Professor Dr S J Konturek, Institute of Physiology, 16 Grzegorzeczka St, 31-531 Krakow, Poland.

duodenal bulb. The mucosal samples were immediately plunged in ice-cold 0.05 M Tris buffer, pH 9.0, and used immediately for the bioassay of prostaglandins as described below.

MEDICATION

The effects of aspirin and paracetamol on gastric mucosa and the mucosal generation of prostaglandins were examined in duodenal ulcer patients and healthy volunteers divided into two groups, each containing six to eight subjects. Aspirin, paracetamol, or placebo was given orally in tablets. Each tablet contained 0.5 g aspirin or paracetamol, which was administered in a total dose of 2.5 g divided into five doses of 0.5 g each: one given before breakfast, after lunch, after supper, at bedtime the day before examination, and in the early morning of the day of examination. In control tests, placebo tablets were administered in the same way as aspirin or paracetamol—that is, five times the day before and once on the day of examination. The study was fully randomised. Medications used in the study were purchased from standard commercial sources, while placebo was obtained from the Upjohn Co.

In addition, one group of the healthy volunteers was used for the study with histamine. The infusion of histamine was performed for 90 minutes in subjects fasted for 12 hours and gastric juice was aspirated throughout the infusion using a standard nasogastric tube. Histamine acid phosphate was given intravenously at a rate of 40 µg/kg/h after blocking H₁-effects with 50 mg mepyramine maleate intramuscularly. Immediately after the infusion of histamine, the nasogastric tube was removed and gastroduodenoscopy was performed.

Duodenal ulcer subjects and volunteers involved in the study were instructed to avoid alcohol, all medications, and highly spiced food. They were requested to record all side-effects, but, for the purpose of this study, the target symptoms described were nausea, vomiting, epigastric pain or burning, and epigastric cramps. The overall subjective symptoms were characterised as minimal, moderate, or severe. About 10 days before the first dose and about five hours after the last dose of medication with aspirin, paracetamol, or placebo the gastroduodenal endoscopy was carried out and the gastric mucosa was observed and graded by the principal investigator, as described by Lanza *et al.*⁸ (Table). In all cases, a 0 grade was required at the initial endoscopy in order for the subject to continue in the study. In all cases four to five biopsy samples were obtained from the body and antrum of the stomach and from the duodenum and immediately plunged in ice-cold 0.05 M Tris buffer, pH 9.0, and used for the bioassay of prostaglandins.

Table Grading of gastric mucosa

Grade	Description
0	No evidence of submucosal haemorrhages
1+	One submucosal haemorrhage
2+	1. More than one submucosal haemorrhage but not numerous or widespread, or 2. Oedema with two or more submucosal haemorrhages
3+	Numerous areas of submucosal haemorrhages
4+	Large area of submucosal haemorrhage with active bleeding or widespread involvement in the stomach

Superficial ulcers were rated as haemorrhages. Invasive ulcers of any size were rated 4+.

GENERATION AND BIOASSAY OF MUCOSAL PROSTAGLANDINS

Mucosal samples, which collectively weighed approximately 30–50 mg, were washed from blood and debris by shaking during five seconds with 1 ml ice-cold Tris buffer and then centrifuging at 9000 *g* for 10 seconds. After the supernatant had been removed, a new volume of Tris buffer was added to residual tissue in the proportion of 0.5 ml/150 mg of tissue weight. This sample was then shaken for 60 seconds at room temperature using a steady speed of a vortex stirrer and centrifuged at 9000 *g* for 15 seconds as described by Whittle.⁹ Supernatant was used for PGI₂-assay immediately after centrifugation and then again after 30 minutes of storage at room temperature to destroy PGI₂ for PGE₂-assay.

The concentration of PGI₂ in the supernatant was determined using its anti-aggregatory properties.¹⁰ Rabbit blood was withdrawn by heart puncture to 3.8% solution of sodium citrate 9:1v/v. Platelet rich plasma (PRP) was prepared by centrifugation of citrated blood at 200 *g* for 10 minutes at room temperature. Platelet rich plasma was aggregated at 37°C in a Born aggregometer with threshold pro-aggregatory concentrations of adenosine diphosphate (2–5 µM). The anti-aggregatory potency of standard PGI₂ was measured by addition of PGI₂ at concentrations of 0.4–10 ng/ml one minute before adenosine diphosphate was added. The percentage of inhibition of the adenosine diphosphate-induced aggregations was plotted against the effective concentrations of PGI₂ to obtain a standard curve. To measure the amount of PGI₂ generated by mucosa, 5–50 µl of the supernatant from incubation samples were added to platelet rich plasma one minute before the addition of ADP. The generation of a PGI₂-like activity in tested samples was calculated by comparing their anti-aggregatory potency with that of synthetic PGI₂. Results are expressed in nanograms of the generated PGI₂/g of tissue weight. The rat stomach strip and rat colon superfusion technique was used to determine the generation of PGE₂ and PGF_{2α}-like activity in the supernatant.¹¹

Rat stomach strip and rat colon were superfused in cascade with pregassed (95% O₂ and 5% CO₂) Krebs solution containing such pharmacological antagonists as phenoxybenzamine (2 µg/ml), propranolol (4 µg/ml), atropine sulphate (0.1 µg/ml), methysergide (0.1 µg/ml), diphenhydramine (0.1 µg/ml), and indomethacin (1 µg/ml). The tone of rat stomach strip and rat colon was recorded with auxotonic levers (2–4 g initial load) using Harvard transducers type 386 connected to a Watanabe multirecorder. Calibration doses of PGE₂, PGF_{2α}, or 25–50 µl of supernatant were infused alternately over the assay organs. Results are expressed as nanograms of the generated PGE₂ per gram of tissue weight.

MEASUREMENT OF MAXIMAL ACID SECRETION

In each subject gastric secretory test was performed using pentagastrin in a dose 2 µg/kg/h producing maximal acid secretion according to the method previously described.¹² Peak-hour acid output was calculated from the sum of the two highest consecutive 15 minute outputs multiplied by 2.

SERUM GASTRIN AND SALICYLATE

Venous blood obtained from the peripheral vein was allowed to clot and serum obtained by centrifugation was stored at –20°C until assayed. Serum gastrin concentrations were measured by radioimmunoassay.¹³ All samples were tested in duplicate in the same assay. Antibody 4562 rabbit antiserum (kindly provided by Professor J F Rehfeld of Aarhus, Denmark) was used at a final dilution of 1:100 000. With this antibody all major molecular forms were measured on nearly equimolar basis, G-34 being about two-thirds as immunoreactive as G-17.

Serum salicylate concentrations were measured by the method of Saltzman.¹⁴

STATISTICAL EVALUATION OF RESULTS

Results are expressed as the means ± SEM. Student's *t* test was used to determine the significance of difference between means, with differences giving a *P* value of less than 0.05 being considered significant.¹⁵

Results

In all mucosal samples tested only the generation of PGE₂-like activity was found, whereas PGI₂ and PGF_{2α} were detected in negligible amounts and these results are not included into the presentation. The mean (±SEM) values of the generated PGE₂-like activity found in the oxyntic and antral portions of the stomach and in the duodenum are presented in Fig. 1. Both in normal subjects and in duodenal

Fig. 1 Schematic presentation of the distribution of PGE₂-like activity in the oxyntic and antral mucosa of the stomach and in the duodenal mucosa of healthy subjects and duodenal ulcer patients.

ulcer patients, antral mucosa tended to generate larger amounts of PGE₂ than oxyntic or duodenal mucosa but the difference was not significant. No significant difference in the generation of PGE₂ was also found between the oxyntic and duodenal mucosa. Healthy volunteers tended to exhibit higher PGE₂ biosynthesising capability in the oxyntic and antral mucosa than duodenal ulcer patients but, again, the difference in the generation of PGE₂ between these two groups of subjects was not statistically significant.

The mean pentagastrin-induced acid output in 14 normal subjects was 19.08 ± 3.33 mmol/h and in 13 duodenal ulcer patients was 21.43 ± 2.05 mmol/h. The mean generation of PGE₂ in oxyntic mucosa of healthy subjects was 325 ± 54 ng/g and that of duodenal ulcer patients was 263 ± 40 ng/g. There was no correlation between maximal acid output and the generation of PGE₂ either in healthy volunteers or in duodenal ulcer patients (Fig. 2).

Fasting serum gastrin in normal subjects averaged about 28.7 ± 4.3 pM and that in duodenal ulcer patients about 34.6 ± 5.1 pM. There was no correlation between serum gastrin concentration and the

Fig. 2 Relationship between maximal acid outputs and the generation of PGE_2 in the oxyntic mucosa in healthy subjects and duodenal ulcer patients.

amounts of generated PGE_2 -like activity both in healthy subjects and duodenal ulcer patients.

In six duodenal ulcer patients and seven healthy subjects PGE_2 -like activity was measured before (placebo) and after ingestion of 2.5 g aspirin. As shown in Fig. 3 the generation of PGE_2 in gastric

Fig. 3 The generation of PGE_2 -like activity in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients before and after oral administration of aspirin. Mean $\pm$ SEM of seven healthy subjects and six duodenal ulcer patients. Asterisks indicate significant ($P < 0.05$) decrease below the control value.

and duodenal mucosa was dramatically and significantly reduced in all subjects tested. In healthy volunteers the fall in the generation of PGE_2 was about 80% of the control level obtained with placebo. In duodenal ulcer patients, the PGE_2 -like activity almost completely disappeared from the duodenal mucosa and was reduced by over 60% in the oxyntic and antral mucosa.

Paracetamol given in the same dosage as aspirin (2.5 g) to six duodenal ulcer patients also significantly reduced the PGE_2 -like activity in the oxyntic and antral mucosa but the degree of this reduction was much less pronounced than after aspirin. No significant change in the PGE_2 biosynthesising capability of the duodenal mucosa was observed.

Endoscopic findings and subjective symptoms were quite different in groups of subjects treated with aspirin and paracetamol. After aspirin ingestion four out of seven healthy subjects complained of nausea and moderate epigastric pain, whereas all six duodenal ulcer patients treated had moderate to severe symptoms of epigastric pain and abdominal

Fig. 4 The generation of PGE_2 -like activity in gastric and duodenal mucosa before and after oral administration of paracetamol in duodenal ulcer patients. Mean $\pm$ SEM of six duodenal ulcer patients. Asterisks indicate significant ($P < 0.05$) decrease below the control value.

cramps. After paracetamol none of the healthy volunteers experienced side-effects and only two out of six duodenal ulcer patients complained of nausea and epigastric pain of mild degree (Fig. 4).

Endoscopic findings correlated quite well with the subjective symptoms. Ingestion of aspirin caused oedema, numerous submucosal haemorrhages and multiple erosions with active bleeding (3 or 4+ endoscopic score) in most of the healthy subjects and in all duodenal ulcer patients examined. After paracetamol ingestion no sign of gastric mucosal injury was noted in three duodenal ulcer patients and in three others only mucosal oedema with single mucosal haemorrhages was observed (2+ endoscopic score). It should be noted that each of the subjects with 3 or 4+ changes in the gastric mucosa reported moderate to severe gastrointestinal symptoms.

The infusion of histamine in a dose used to produce maximal secretory response caused a small but significant decrease in PGE_2 biosynthesising capability of gastric and duodenal mucosa in five out of six healthy subjects (Fig. 5). The decrease in the generated PGE_2 -like activity ranged around 30% and was accompanied by marked mucosal damage (3+) in all examined subjects. The major symptoms

Fig. 5 The effect of histamine infusion on the generation of PGE_2 -like activity of healthy subjects. Mean $\pm$ SEM of six observations in six subjects. Asterisks indicate significant ($P < 0.05$) decrease below the control value.

observed during histamine infusion included headache, flushing, and mild epigastric discomfort.

The serum salicylate levels that were obtained the morning of endoscopy after aspirin ingestion were comparable in healthy volunteers and in duodenal ulcer patients. Mean serum level was 125 ± 29 µg/ml for healthy subjects and 134 ± 37 µg/ml for duodenal ulcer patients.

Discussion

This study shows that human gastric and duodenal mucosa is capable of generating large amounts of bioassayable PGE_2 -like activity and negligible amounts of PGI_2 or $\text{PGF}_{2\alpha}$. The gastric mucosa of duodenal ulcer patients tends to generate smaller amounts of PGE_2 than that of healthy subjects but the difference is not statistically significant. As far as we know, this is the first report of the mucosal distribution of prostaglandins in healthy men and in duodenal ulcer patients. Previous studies tried to determine the prostaglandin levels in plasma and in gastric juice in duodenal ulcer patients. Hinsdale *et al.*⁶ found significantly reduced levels of prostaglandins in the plasma and gastric juice of the duodenal ulcer patients under basal conditions and suggested that the prostaglandin deficiency may play a role in the pathogenesis of peptic ulcer disease. On the other hand, Baker *et al.*³, using a highly sensitive radioimmunoassay system to measure PGE_2 , reported that plasma PGE concentrations in duodenal ulcer patients were within the normal range and were not related to gastric secretory status, serum gastrin level, or a specific diagnosis in dyspeptic patients. The discrepancy between the results of plasma prostaglandin reported by various workers^{3,6,7} could be attributed, at least in part, to the difficulties in the radioimmunoassay of prostaglandins and their almost complete removal from the circulation after a single passage through the lungs.¹⁶

Because of the above problems we decided to use the quick extraction and immediate bioassay technique; in the past this helped in the discovery of the major products of biotransformation of arachidonate *via* the cyclooxygenase pathway. We found that PGE_2 is the predominant form of prostaglandins in the human mucosa and that $\text{PGF}_{2\alpha}$ and PGI_2 can be detected by the bioassay system in negligible amounts. This may not mean that the human mucosa is unable to generate these prostaglandins but that these compounds are synthesised in relatively smaller amounts, just below the threshold of detection by our bioassay technique. In addition, human gastric mucosa may generate other products of arachidonate metabolism, such as thromboxanes, which could mask the synthesis of PGI_2 .¹⁷

Our results indicate that the generation of PGE₂ by the oxyntic mucosa does not show a statistically significant difference between the duodenal ulcer patients and healthy subjects and that this generation is not correlated with the gastric acid secretory capacity or serum gastrin level. Thus, it is unlikely that the mucosal prostaglandins play an important role in the pathogenesis of ulcer disease as suggested by Hindale *et al.*⁶ or in the local feedback control of gastric secretion as proposed by Baker and his colleagues.³

The major finding of this study is the demonstration that aspirin, the most widely used representative of the non-steroidal anti-inflammatory compounds, causes dramatic reduction in the capacity of the gastric and duodenal mucosa to biosynthesise prostaglandins and that it is closely correlated with the subjective symptoms and the marked gastric mucosal injury. The fact that aspirin inhibits the biosynthesis of prostaglandins in other tissues by irreversible inactivation of the prostaglandin synthetase system^{18,19} is well recognised, but our report demonstrates for the first time the deficiency of gastric mucosal prostaglandins attributable to aspirin treatment in man and its relationship to gastrointestinal side-effects and gastric mucosal lesions. Aspirin is known to be poorly tolerated by duodenal ulcer patients²⁰ and our study suggests that this intolerance is caused by severe damage to the gastric mucosa probably attributable to the deficiency of the mucosal generation of prostaglandins. This is supported also by our observation that duodenal ulcer patients receiving paracetamol, another widely used analgesic and antipyretic salicylate-like agent,²¹ reported little or no intolerance and this was accompanied by only mild gastroscopic mucosal changes and small reduction in mucosal generation of PGE₂. The study with both aspirin and paracetamol suggests that mucosal prostaglandins play an important role in the integrity of gastric mucosa and that the suppression of the generation of mucosal prostaglandins by non-steroidal anti-inflammatory compounds makes the mucosa more vulnerable to chemical injury and results in visible damage.

Baker *et al.*³ reported that the stimulated gastric acid output is significantly correlated with the output of PGE₂ into gastric juice, suggesting that the mucosal prostaglandins may play a role in the local control of gastric acid secretion. To test this hypothesis, we designed experiments in which the mucosal generation of prostaglandins was measured immediately after the infusion of histamine in a dose producing maximal gastric acid secretion was discontinued. The results of this study show that after secretory stimulation by histamine the genera-

tion of mucosal prostaglandins tends to decrease and, therefore, the mucosal changes in prostaglandins may not be paralleled by prostaglandin changes in the gastric juice. Thus we failed to confirm the notion that mucosal prostaglandins may be involved in the feedback control of gastric secretion.^{3,4} However, our study confirms²² that histamine administration may cause marked endoscopic mucosal damage without marked changes in the mucosal generation of prostaglandins. Thus, it appears that damage to the mucosa does not necessarily involve a reduction in the generation of mucosal prostaglandins and may, therefore, not be mediated by the deficiency of mucosal prostaglandins.

References

- Benett A, Stamford IF, Unger WG. Prostaglandin E₂ and gastric acid secretion in man. *J Physiol* 1973; **229**: 349–60.
- Cheung LY, Jubiz W, Moore JG. Gastric prostaglandin E₂ output during basal and stimulated acid secretion in normal subjects and patients with duodenal ulcer. *J Surg Res* 1976; **20**: 369–72.
- Baker R, Jaffe BM, Venables CW. Endogenous prostaglandins in peptic ulcer disease. *Gut* 1979; **20**: 394–9.
- Horton EW. Hypotheses on physiological roles of prostaglandins. *Physiol Rev* 1969; **49**: 122–61.
- Robert A. Cytoprotection by prostaglandins. *Gastroenterology* 1979; **77**: 761–7.
- Hinsdale JG, Engel JJ, Wilson DE. Prostaglandin E₂ in peptic ulcer disease. *Prostaglandins* 1974; **6**: 459–500.
- Baker R, Jaffe BM, Reed JD, Shaw B, Venables CW. Are prostaglandins deficient in peptic ulceration? *Gut* 1977; **18**: 950–1.
- Lanza FL, Rayer GL, Nelson RS, Chen TT, Seckman CE, Rack MF. The effects of ibuprofen, indomethacin, aspirin, naproxen and placebo on the gastric mucosa of normal volunteers. *Digest Dis Sci* 1979; **24**: 823–8.
- Whittle BJR. Potential endogenous inhibitor of prostaglandin synthetase in plasma failure to inhibit cyclooxygenase in platelets and the gastric mucosa. *J Pharm Pharmacol* 1978; **30**: 467–8.
- Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which prevents platelet aggregation. *Prostaglandins* 1976; **12**: 685–9.
- Vane JR. The use of isolated organs for detecting active substances in the circulating blood. *Br J Pharmacol Chemother* 1964; **23**: 360–73.
- Konturek SJ, Lankosz J. Pentapeptide infusion test. *Scand J Gastroenterol* 1967; **2**: 112–7.
- Yalow RS, Berson SA. Radioimmunoassay of gastrin. *Gastroenterology* 1970; **58**: 1–14.
- Saltzman A. Fluorophotometric method for the estimation of salicylate in blood. *J Biol Chem* 1948; **174**: 399–404.
- Siegel S. *Nonparametric Statistics for the Behavioral Sciences*. New York: McGraw-Hill, 1956.

- ¹⁶Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. *Nature* 1970; **225**: 600-4.
- ¹⁷LeDuc LE, Needleman P. Regional localization of prostacyclin and thromboxane synthesis in dog stomach and intestinal tract. *J Pharmacol Exp Ther* 1979; **211**: 181-8.
- ¹⁸Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature* 1971; **231**: 232-5.
- ¹⁹Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. *Nature* 1971; **231**: 235-7.
- ²⁰Cooke AR. Drug damage of the gastroduodenum. In: Sleisenger MH, Fordtran JS, eds. *Gastrointestinal disease*. Philadelphia: Saunders, 1978: 807-26.
- ²¹Woodbury DM, Fingl E. Analgesic-antipyretics anti-inflammatory agents, and drugs employed in the therapy of gout. In: Goodman LS, Gilman A, eds. *The pharmacological basis of therapeutics*. New York: MacMillan, 1975: 325-50.
- ²²Siegel H, Harbilas E, Katz D, Glass GBJ. Gastric erosions and mucosal hemorrhage during the augmented histamine test. *Gastroenterology* 1967; **52**: 1120.